2[4]Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents.J Am Acad Dermatal,2002,46(1):1-23.
3[5]Cball LA,Tso JY,Melrose J,et al.HuM291(Nuvion),a humanized Fc receptor-nonbinding antibody against CD3,anergizes peripheral blood T cells as partial agonist of the T cell receptor.Transplantation,2001,71(7):941-950.
4[6]Skov L,Kragballe K,Zachariae C,et al.HuMax-CD4:a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.Arch Dermatol,2003,139(11):1433-1439.
5[7]Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4.J Autoimmun,1998,11(1):53-62.
6[8]Gottlieb AB,Krueger JG,Wittkowski K,et al.Psoriasis as a model for T-cell-mediated disease:immunobiologic and clinical affects of treatment with multiple doses of efalizumab,an anti-CD11a antibody.Arch Dermatol,2002,1381(5):591-600.
7[9]Krueger JG,Waiters IB,Miyazawa M,et al.Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.J Am Acad Dermatol,2000,43(3):448-458.
8[10]da Silva AJ,Brickelmaier M,Majeau GR,et al.Alefacept,an immunomodulatory recombinant LFA-3/IgG1 fusion protein,induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+)cells.J Immunol,2002,168(9):4462-4471.
9[11]Ellis CN,Krueger GG.Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.N Engl J Med,2001,345(4):248-255.
2[4]Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents.J Am Acad Dermatal,2002,46(1):1-23.
3[5]Cball LA,Tso JY,Melrose J,et al.HuM291(Nuvion),a humanized Fc receptor-nonbinding antibody against CD3,anergizes peripheral blood T cells as partial agonist of the T cell receptor.Transplantation,2001,71(7):941-950.
4[6]Skov L,Kragballe K,Zachariae C,et al.HuMax-CD4:a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.Arch Dermatol,2003,139(11):1433-1439.
5[7]Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4.J Autoimmun,1998,11(1):53-62.
6[8]Gottlieb AB,Krueger JG,Wittkowski K,et al.Psoriasis as a model for T-cell-mediated disease:immunobiologic and clinical affects of treatment with multiple doses of efalizumab,an anti-CD11a antibody.Arch Dermatol,2002,1381(5):591-600.
7[9]Krueger JG,Waiters IB,Miyazawa M,et al.Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.J Am Acad Dermatol,2000,43(3):448-458.
8[10]da Silva AJ,Brickelmaier M,Majeau GR,et al.Alefacept,an immunomodulatory recombinant LFA-3/IgG1 fusion protein,induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+)cells.J Immunol,2002,168(9):4462-4471.
9[11]Ellis CN,Krueger GG.Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.N Engl J Med,2001,345(4):248-255.
